To investigate whether combining trastuzumab with inhibitor TFBG might result in additive or synergistic effects on the growth of HER2-positive gastric cancer, we detected the effect of the trastuzumab–TFBG combination on tumor growth both in vitro and in vivo. The gene discussed is ERBB2; the disease is neoplasm.